成都先导终止收购海纳医药65%股权 首季净利激增102.9%加码全球化布局

Group 1 - Chengdu XianDao announced the termination of its major asset restructuring plan to acquire a 65% stake in Nanjing Haina Pharmaceutical Technology Co., Ltd. after nearly three months of planning [1] - The acquisition was intended to create a "strong alliance" but faced disagreements on key terms such as transaction price, performance commitments, and payment methods during the due diligence phase [1] - The termination of the restructuring will not trigger any breach of contract liabilities and is stated to have no adverse impact on the company's business and financial status [1] Group 2 - Chengdu XianDao focuses on the discovery and optimization of small molecules and nucleic acid new drugs, developing an internationally leading DNA-encoded compound library (DEL) technology platform [2] - The company reported a revenue of 427 million yuan in 2024, a year-on-year increase of 14.99%, and a net profit attributable to shareholders of 51.36 million yuan, up 26.13% [2] - In the first quarter of 2025, the company maintained a steady growth trend with a revenue of 107 million yuan, a slight decrease of 0.60%, while the net profit attributable to shareholders increased by 102.90% to 28.28 million yuan [2]